Immutep Adjusts ADS Ratio to Meet Nasdaq Listing Requirements
Event summary
- Immutep changes its ADS ratio from 1:10 to 1:200, effective September 28, 2026.
- The move is a reverse split equivalent, reducing ADS count from ~32.8M to ~1.64M.
- Nasdaq compliance triggered by ADS price falling below $1 for 30 consecutive days.
- Ordinary shares on ASX remain unaffected; no change in total issued shares.
- Fractional entitlements will be paid in cash within 1-2 days of the effective date.
The big picture
Immutep's ADS ratio adjustment is a defensive move to comply with Nasdaq's minimum bid price requirement, a common challenge for biotech firms with low-priced shares. The change reflects broader trends in capital markets where listing standards push companies toward structural adjustments to maintain access to U.S. investors. The strategic focus remains on clinical progress, but market positioning through share structure optimization is critical for sustaining investor confidence.
What we're watching
- Compliance Success
- Whether Immutep can sustain ADS price above $1 to maintain Nasdaq listing.
- Investor Impact
- How the reduced ADS count affects liquidity and trading volume.
- Operational Focus
- The pace at which Immutep advances its clinical development programs amid market adjustments.
Related topics